Lv11
18 积分 2021-05-31 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5小时前
待确认
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
4天前
已完结
Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements
2个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
2个月前
已关闭
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination
2个月前
已完结
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
3个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
4个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
4个月前
已完结
Pan-cancer human brain metastases atlas at single-cell resolution
4个月前
已完结
皖公网安备34019202002308
